IND-话题@MedSci

#IND#

133篇内容 | 3048人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1469175, encodeId=e89914691e534, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, objectTitle=FXR激动剂ASC42治疗NASH：美国FDA已批准IND, objectType=article, longId=202037, objectId=84d120203ed5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84d120203ed5, replyNumber=0, likeNumber=63, createdTime=2020-10-14, rootId=0, userName=xiaogang319, userId=16377007930, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84d120203ed5, moduleTitle=FXR激动剂ASC42治疗NASH：美国FDA已批准IND, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84d120203ed5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469174, encodeId=362014691e43d, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, objectTitle=Acta Med Indones：口服N-乙酰半胱氨酸补充剂可改善急性心肌梗死患者的免疫系统, objectType=article, longId=201412, objectId=b1b6201412f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b1b6201412f9, replyNumber=0, likeNumber=117, createdTime=2020-10-01, rootId=0, userName=xiaogang319, userId=16377007930, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b1b6201412f9, moduleTitle=Acta Med Indones：口服N-乙酰半胱氨酸补充剂可改善急性心肌梗死患者的免疫系统, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b1b6201412f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469173, encodeId=3ecd14691e3ae, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, objectTitle=多发性硬化症药物或添新成员：FDA批准ANK-700治疗多发性硬化症的IND, objectType=article, longId=201325, objectId=718d20132547, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=718d20132547, replyNumber=0, likeNumber=91, createdTime=2020-09-30, rootId=0, userName=xiaogang319, userId=16377007930, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=718d20132547, moduleTitle=多发性硬化症药物或添新成员：FDA批准ANK-700治疗多发性硬化症的IND, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=718d20132547)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469172, encodeId=a3d414691e2b7, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, objectTitle=晚期实体瘤的新希望！FDA批准MOR210 / TJ210治疗晚期实体瘤的IND, objectType=article, longId=200901, objectId=302a20090170, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=302a20090170, replyNumber=0, likeNumber=82, createdTime=2020-09-20, rootId=0, userName=xiaogang319, userId=16377007930, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=302a20090170, moduleTitle=晚期实体瘤的新希望！FDA批准MOR210 / TJ210治疗晚期实体瘤的IND, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=302a20090170)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469171, encodeId=a48e14691e17b, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, objectTitle=Blood：Kindlin-3介导β2整合素激活的分子机制, objectType=article, longId=199945, objectId=421f1999454c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=421f1999454c, replyNumber=0, likeNumber=72, createdTime=2020-08-28, rootId=0, userName=xiaogang319, userId=16377007930, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=421f1999454c, moduleTitle=Blood：Kindlin-3介导β2整合素激活的分子机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=421f1999454c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469170, encodeId=1b5514691e07f, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, objectTitle=Indian J Dent Res：猪胶原基质联合冠向瓣治疗Miller I型和II型牙龈退缩, objectType=article, longId=199736, objectId=1a93199e36ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a93199e36ab, replyNumber=0, likeNumber=81, createdTime=2020-08-22, rootId=0, userName=xiaogang319, userId=16377007930, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a93199e36ab, moduleTitle=Indian J Dent Res：猪胶原基质联合冠向瓣治疗Miller I型和II型牙龈退缩, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a93199e36ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469169, encodeId=0d3f1469169de, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, objectTitle=**iPSC衍生的CAR-T细胞疗法：IND已获FDA批准, objectType=article, longId=197391, objectId=8b4a19e3919e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b4a19e3919e, replyNumber=0, likeNumber=74, createdTime=2020-07-13, rootId=0, userName=xiaogang319, userId=16377007930, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b4a19e3919e, moduleTitle=**iPSC衍生的CAR-T细胞疗法：IND已获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b4a19e3919e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469168, encodeId=4a621469168ee, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, objectTitle=异源细胞疗法FCR001治疗重度硬皮病：IND已获FDA批准, objectType=article, longId=197299, objectId=56fc19e29943, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56fc19e29943, replyNumber=0, likeNumber=75, createdTime=2020-07-11, rootId=0, userName=xiaogang319, userId=16377007930, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56fc19e29943, moduleTitle=异源细胞疗法FCR001治疗重度硬皮病：IND已获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=56fc19e29943)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469167, encodeId=845c146916edc, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, objectTitle=Indian J Dent Res：ώ-3脂肪酸在慢性牙周炎治疗中的辅助治疗功效, objectType=article, longId=196395, objectId=579a196395b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=579a196395b3, replyNumber=0, likeNumber=104, createdTime=2020-06-25, rootId=0, userName=xiaogang319, userId=16377007930, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=579a196395b3, moduleTitle=Indian J Dent Res：ώ-3脂肪酸在慢性牙周炎治疗中的辅助治疗功效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=579a196395b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469166, encodeId=cbca146916681, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, objectTitle=Indoor Air：对长途汽车工作人员进行过敏性鼻炎风险预测的诺模图构建 , objectType=article, longId=195526, objectId=092e19552644, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=092e19552644, replyNumber=0, likeNumber=65, createdTime=2020-06-11, rootId=0, userName=xiaogang319, userId=16377007930, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=092e19552644, moduleTitle=Indoor Air：对长途汽车工作人员进行过敏性鼻炎风险预测的诺模图构建 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=092e19552644)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469165, encodeId=2fb31469165d8, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, objectTitle=间充质干细胞BX-U001治疗风湿性关节炎的IND申请，获得FDA批准, objectType=article, longId=195464, objectId=7a1c19546415, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a1c19546415, replyNumber=0, likeNumber=78, createdTime=2020-06-09, rootId=0, userName=xiaogang319, userId=16377007930, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a1c19546415, moduleTitle=间充质干细胞BX-U001治疗风湿性关节炎的IND申请，获得FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a1c19546415)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469164, encodeId=e1e91469164c5, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, objectTitle=抗CD38抗体-药物偶联物（ADC）STI-6129治疗淀粉样变性：FDA已批准IND, objectType=article, longId=194877, objectId=616f1948e72f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=616f1948e72f, replyNumber=0, likeNumber=82, createdTime=2020-05-29, rootId=0, userName=xiaogang319, userId=16377007930, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=616f1948e72f, moduleTitle=抗CD38抗体-药物偶联物（ADC）STI-6129治疗淀粉样变性：FDA已批准IND, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=616f1948e72f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469163, encodeId=ef681469163ac, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, objectTitle=CRISPR编辑的iPSC衍生细胞疗法FT538：FDA已批准IND, objectType=article, longId=194509, objectId=c38719450955, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c38719450955, replyNumber=0, likeNumber=82, createdTime=2020-05-23, rootId=0, userName=xiaogang319, userId=16377007930, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c38719450955, moduleTitle=CRISPR编辑的iPSC衍生细胞疗法FT538：FDA已批准IND, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c38719450955)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469162, encodeId=cf1d14691628a, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, objectTitle=FDA批准BCL-2口服选择性抑制剂ZN-d5的IND申请，用于治疗血液系统恶性肿瘤, objectType=article, longId=193383, objectId=4d63193383b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d63193383b1, replyNumber=0, likeNumber=73, createdTime=2020-05-04, rootId=0, userName=xiaogang319, userId=16377007930, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d63193383b1, moduleTitle=FDA批准BCL-2口服选择性抑制剂ZN-d5的IND申请，用于治疗血液系统恶性肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d63193383b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469161, encodeId=7e991469161f3, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, objectTitle=Indian J Dent Res：含有精油和姜黄素的漱口水在慢性类风湿性关节炎患者中作为牙周非手术治疗的功效, objectType=article, longId=192560, objectId=85e41925603a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85e41925603a, replyNumber=0, likeNumber=95, createdTime=2020-04-21, rootId=0, userName=xiaogang319, userId=16377007930, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85e41925603a, moduleTitle=Indian J Dent Res：含有精油和姜黄素的漱口水在慢性类风湿性关节炎患者中作为牙周非手术治疗的功效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85e41925603a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469160, encodeId=941714691602c, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, objectTitle=Am J Ind Med：职业噪音接触和不对称听力损失群体研究 , objectType=article, longId=191762, objectId=b379191e629e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b379191e629e, replyNumber=0, likeNumber=94, createdTime=2020-04-10, rootId=0, userName=xiaogang319, userId=16377007930, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b379191e629e, moduleTitle=Am J Ind Med：职业噪音接触和不对称听力损失群体研究 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b379191e629e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469159, encodeId=d55a1469159aa, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, objectTitle=中国MNPA批准细胞疗法GC007g治疗CD19阳性复发难治B细胞急性淋巴细胞白血病的IND, objectType=article, longId=191470, objectId=27641914e046, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27641914e046, replyNumber=0, likeNumber=63, createdTime=2020-04-06, rootId=0, userName=xiaogang319, userId=16377007930, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27641914e046, moduleTitle=中国MNPA批准细胞疗法GC007g治疗CD19阳性复发难治B细胞急性淋巴细胞白血病的IND, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=27641914e046)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469158, encodeId=f94214691584e, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, objectTitle=FDA批准TJM2治疗COVID-19细胞因子释放综合征（CRS）的IND, objectType=article, longId=191466, objectId=71e41914668d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=71e41914668d, replyNumber=0, likeNumber=73, createdTime=2020-04-06, rootId=0, userName=xiaogang319, userId=16377007930, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=71e41914668d, moduleTitle=FDA批准TJM2治疗COVID-19细胞因子释放综合征（CRS）的IND, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=71e41914668d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469157, encodeId=cf1f146915e3d, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, objectTitle=Algernon已提交Pre-IND申请，以进行Ifenprodil治疗新冠肺炎的临床试验, objectType=article, longId=190020, objectId=b9e3190020b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9e3190020b9, replyNumber=0, likeNumber=72, createdTime=2020-03-16, rootId=0, userName=xiaogang319, userId=16377007930, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9e3190020b9, moduleTitle=Algernon已提交Pre-IND申请，以进行Ifenprodil治疗新冠肺炎的临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b9e3190020b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469156, encodeId=16381469156de, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, objectTitle=leronlimab（PRO 140）治疗新冠肺炎的II期临床试验方案获得IND, objectType=article, longId=189616, objectId=bc9018961683, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc9018961683, replyNumber=0, likeNumber=83, createdTime=2020-03-11, rootId=0, userName=xiaogang319, userId=16377007930, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc9018961683, moduleTitle=leronlimab（PRO 140）治疗新冠肺炎的II期临床试验方案获得IND, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc9018961683)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

IND

2020-05-29

xiaogang319 (审核中...)

前往app查看评论内容

#IND#

FXR激动剂ASC42治疗NASH：美国FDA已批准IND

2020-10-14

xiaogang319 (审核中...)

前往app查看评论内容

#IND#

Acta Med Indones：口服N-乙酰半胱氨酸补充剂可改善急性心肌梗死患者的免疫系统

2020-10-01

xiaogang319 (审核中...)

前往app查看评论内容

#IND#

多发性硬化症药物或添新成员：FDA批准ANK-700治疗多发性硬化症的IND

2020-09-30

xiaogang319 (审核中...)

前往app查看评论内容

#IND#

晚期实体瘤的新希望！FDA批准MOR210 / TJ210治疗晚期实体瘤的IND

2020-09-20

xiaogang319 (审核中...)

前往app查看评论内容

#IND#

Blood：Kindlin-3介导β2整合素激活的分子机制

2020-08-28

xiaogang319 (审核中...)

前往app查看评论内容

#IND#

Indian J Dent Res：猪胶原基质联合冠向瓣治疗Miller I型和II型牙龈退缩

2020-08-22

xiaogang319 (审核中...)

前往app查看评论内容

#IND#

**iPSC衍生的CAR-T细胞疗法：IND已获FDA批准

2020-07-13

xiaogang319 (审核中...)

前往app查看评论内容

#IND#

异源细胞疗法FCR001治疗重度硬皮病：IND已获FDA批准

2020-07-11

xiaogang319 (审核中...)

前往app查看评论内容

#IND#

Indian J Dent Res：ώ-3脂肪酸在慢性牙周炎治疗中的辅助治疗功效

2020-06-25

xiaogang319 (审核中...)

前往app查看评论内容

#IND#

Indoor Air：对长途汽车工作人员进行过敏性鼻炎风险预测的诺模图构建

2020-06-11

xiaogang319 (审核中...)

前往app查看评论内容

#IND#

间充质干细胞BX-U001治疗风湿性关节炎的IND申请，获得FDA批准

2020-06-09

xiaogang319 (审核中...)

前往app查看评论内容

#IND#

抗CD38抗体-药物偶联物（ADC）STI-6129治疗淀粉样变性：FDA已批准IND

2020-05-29

xiaogang319 (审核中...)

前往app查看评论内容

#IND#

CRISPR编辑的iPSC衍生细胞疗法FT538：FDA已批准IND

2020-05-23

xiaogang319 (审核中...)

前往app查看评论内容

#IND#

FDA批准BCL-2口服选择性抑制剂ZN-d5的IND申请，用于治疗血液系统恶性肿瘤

2020-05-04

xiaogang319 (审核中...)

前往app查看评论内容

#IND#

Indian J Dent Res：含有精油和姜黄素的漱口水在慢性类风湿性关节炎患者中作为牙周非手术治疗的功效

2020-04-21

xiaogang319 (审核中...)

前往app查看评论内容

#IND#

Am J Ind Med：职业噪音接触和不对称听力损失群体研究

2020-04-10

xiaogang319 (审核中...)

前往app查看评论内容

#IND#

中国MNPA批准细胞疗法GC007g治疗CD19阳性复发难治B细胞急性淋巴细胞白血病的IND

2020-04-06

xiaogang319 (审核中...)

前往app查看评论内容

#IND#

FDA批准TJM2治疗COVID-19细胞因子释放综合征（CRS）的IND

2020-04-06

xiaogang319 (审核中...)

前往app查看评论内容

#IND#

Algernon已提交Pre-IND申请，以进行Ifenprodil治疗新冠肺炎的临床试验

2020-03-16

xiaogang319 (审核中...)

前往app查看评论内容

#IND#

leronlimab（PRO 140）治疗新冠肺炎的II期临床试验方案获得IND

2020-03-11

科室
- - 订阅+
  - 更多科室
工具
服务